Ottawa scales back drug price reforms that would have cost big pharma billions

Ottawa is dramatically scaling back regulatory changes to reduce the cost of drugs, five years after heralding them as a once-in-a-generation effort to cut costs and shave billions off industry profits. The federal reprieve for pharmaceutical companies follows a series of court challenges, which the government either lost or remain outstanding.

Read the source article at The Globe and Mail
2022-04-21 10:22:25